Home / Pharma Healthcare / EMEA (Europe, Middle East and Africa) Gastrointestinal Therapeutics Market Report 2017

EMEA (Europe, Middle East and Africa) Gastrointestinal Therapeutics Market Report 2017

  • Id : RNR-158839
  • Category : Pharma Healthcare
  • Publish Date : 17
  • Pages : 129
  • Format : PDF
License Type

Description
In this report, the EMEA Gastrointestinal Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Gastrointestinal Therapeutics for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Gastrointestinal Therapeutics market competition by top manufacturers/players, with Gastrointestinal Therapeutics sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Johnson & Johnson
    AbbVie
    Allergan
    Takeda
    Novartis
    Pfizer
    GlaxoSmithKline
    Merck
    UCB (Belgium)
    F. Hoffmann-La Roche
    Eli Lilly
    AstraZeneca
    Procter & Gamble
    Eisai
    Shire Pharmaceuticals
    Ferring Pharmaceuticals
    Kyowa Hakko Kirin
    Salix Pharmaceuticals
    Ono Pharmaceutical
    TSD Japan
    RedHill Biopharma
    Kaken Pharmaceutical
    Amgen
    Synergy Pharmaceuticals
    Ajinomoto
    Kissei Pharmaceutical
    Hutchison Medi Pharma

On the basis of product, this report displays the sales volume (K Pcs), revenue (Million USD), product price (USD/Pcs), market share and growth rate of each type, primarily split into
    Tablets
    Injection

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Pcs), market share and growth rate of Gastrointestinal Therapeutics for each application, including
    IBD
    Irritable Bowel Syndrome (IBS)
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.